Why the study?
Is nonplatelet thromboxane generation associated with the risk of death, transplant, or need for mechanical support in patients with heart failure?
Is nonplatelet thromboxane generation associated with the risk of death, transplant, or need for mechanical support in patients with heart failure?
Measurement of urine thromboxane metabolites may serve as a useful prognostic surrogate for cardiovascular hemodynamics and outcomes in heart failure.
Answers are grounded in this paper and cite their sources.
May inform HF prognosis via urine thromboxane; leaves open whether it is a modifiable target.
Nonplatelet thromboxane generation in heart failure is independently associated with risk of death, transplant, or need for mechanical support. Measurement of urine thromboxane metabolites using a clinically available assay may be a useful surrogate for invasive measurement of cardiovascular hemodynamics and performance that could provide prognostic information and facilitate tailoring of therapy in patients with heart failure. Inhibiting thromboxane generation or its biological effects is a potential strategy for improving cardiovascular performance and outcomes in heart failure.
No takes yet. Share an insight, caveat, or question.
Hariri et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: